|
Market Research Report
SPECIAL REPORT: Can Innovation Supplant Convention in Sarcoidosis Treatment?
|
SPECIAL REPORT: Can Innovation Supplant Convention in Sarcoidosis Treatment? published by Decision Resources, Inc. in September, 2009. This report consists of 24 Pages and the price starts from US $ 9200.
Abstract
Introduction
“I' d love there to be a better agent,” says a thought leader on
the current state of sarcoidosis treatment. Many sarcoidosis patients require
little or no treatment, but patients with chronic disease need a therapy that
is safer than the corticosteroids that have become the mainstay treatment for
the disease. Because substantial market constraints have limited development
in this therapeutic area, only a few novel agents are in the pipeline.
However, opportunity remains for an agent that can address some of the unmet
needs in this market.
Questions Answered in This Report
- Sarcoidosis is an infl ammatory disease that is hallmarked by " the
development of granulomas. What organ systems are affected by sarcoidosis?
How is the disease diagnosed? What is the prognosis for patients with
sarcoidosis?
- Sarcoidosis affects only a small percentage of the population. How many
people were hospitalized with sarcoidosis in 2008? Is this population expected
to grow?
- Patients with chronic sarcoidosis will require multiple treatment courses
throughout their lifetime. What are the current treatments for sarcoidosis?
What are their benefi ts and drawbacks? How do emerging treatments compare
with current offerings?
- Reimbursement challenges loom large in this market. What effect are
they having on sales? How might companies overcome these challenges? What are
the ideal characteristics of an agent positioned to capture the sarcoidosis
market?
Scope
- Overview of sarcoidosis: Pathophysiology and etiology, symptoms,
diagnosis.
- Epidemiology: Decision Resources epidemiology analysis of the
diagnosed incidence and the number of patients hospitalized with sarcoidosis
in the United States, 2008-2018.
- Current treatments: Corticosteroids, methotrexate, antimalarials,
TNF-α inhibitors.
- Emerging treatments: Celgene' s apremilast, MondoBiotech/Biogen
Idec' s aviptadil, Centocor/ Medarex' s Stelara, ongoing academic research.
- Market: 2008 sales, opportunities and challenges for emerging
agents, remaining unmet need, outlook for the sarcoidosis market.
- Primary research: Interviews with thought leaders in sarcoidosis.
Companies Mentioned in This Report
- Abbott
- Actelion
- Amgen
- Biogen Idec
- Celgene
- Centocor
- Eisai
- Gilead
- Janssen
- Medarex
- Mitsubishi Tanabe
- MondoBiotech
- Roche
- Sanofi -Aventis
- Schering-Plough
- Takeda
- UCB
- Wyeth
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Sarcoidosis
- Symptoms
- Pathophysiology and Etiology
- Diagnosis
- Epidemiology
- Overview
- Disease Defi nition
- Methods
- Subpopulations
- Current Therapies
- Corticosteroids
- Methotrexate
- Antimalarials
- TNF-Alpha Inhibitors
- Other Treatments
- Emerging Therapies
- Academic Research
- Agents Seeking Approval for Sarcoidosis: Celgene' s Apremilast,
Centocor/Medarex' s Stelara, and MondoBiotech/Biogen Idec' s Aviptadil
- Outlook
- Bibliography
Tables
- 1. The Scadding Criteria for Sarcoidosis Staging
- 2. Current Therapies Used in the Treatment of Sarcoidosis
- 3. Academic and Government-Initiated Clinical Trials in Sarcoidosis
- 4. Agents in Development for the Treatment of Sarcoidosis
- 5. Sales of Agents to Treat Sarcoidosis in the United States, 2008
Figures
- 1. Granuloma Formation in Sarcoidosis
- 2. Diagnosed Incidence of Sarcoidosis in the United States, 2008-2018
|
